The search for new sterilizing anti-tuberculosis drugs

Frontiers in Bioscience

Volumn 9, Issue , 2004, Pages 1059-1072

  Mitchison, Denis A ^a  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Bacterium; Disease; Infection; Lung; Micro aerophilie; Microorganisms; Persisters; Review; Sterilizing; TB; Therapeutics; Treatment; Tuberculosis

Indexed keywords

AMINOSALICYLIC ACID; CHEMOSTERILANT; ETHAMBUTOL; PYRAZINAMIDE; RIFAMPICIN; STREPTOMYCIN; TUBERCULOSTATIC AGENT;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; BACTERIAL GROWTH; BACTERIAL METABOLISM; CELLULAR IMMUNITY; DRUG ACTIVITY; DRUG INDICATION; DRUG RESEARCH; DRUG RESPONSE; DRUG SCREENING; MICROBIAL POPULATION DYNAMICS; MULTIDRUG RESISTANCE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; OXYGEN TENSION; PHENOTYPE; REVIEW; TUBERCULOSIS; ANIMAL; DISEASE MODEL; DRUG EFFECT; HUMAN; LUNG TUBERCULOSIS; MICROBIOLOGY; MOUSE; PATHOGENICITY; PATHOLOGY;

ANIMALIA; BACILLI; BACTERIA (MICROORGANISMS); MYCOBACTERIUM; MYCOBACTERIUM TUBERCULOSIS;

ANIMALS; ANTITUBERCULAR AGENTS; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; HUMANS; MICE; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS, PULMONARY;

EID: 2442685844     PISSN: 27686701     EISSN: 27686698     Source Type: Journal    
DOI: 10.2741/1293     Document Type: Review

References (59)

1. O'Brien R. & P.P. Nunn: The need for new drugs against Tuberculosis - obstacles, opportunities, and next steps. Am J Respir Crit Care Med 162, 1055-1058 (2001)
2. Canetti G: The tubercle bacillus in the pulmonary lesion of man, pp 15-17. Springer, New York. (1955)
3. Grosset J: Mycobacterium tuberculosis in the extracellular compartment: an underestimated adversary. Antimicrob Agents Chemother 47, 833-836 (2003)
4. Brindle R.J., P.P. Nunn, W. Githui, B.W. Allen, S. Gathua & P. Waiyaki: Quantitative bacillary response to treatment in HIV-associated pulmonary tuberculosis. Am Rev Respir Dis 147, 958-961 (1993)
5. Brindle R, J., Odhiambo & D. Mitchison: Serial counts of Mycobacterium tuberculosis in sputum as surrogate markers of the sterilising activity of rifampicin and pyrazinamide in treating pulmonary tuberculosis. BMC Pulmonary Medicine 1,2. (2001)
6. Hernandez-Pando R, M. Jeyanathan, G. Mengistu, D. Aguilar, H. Orozco, M. Harboe, G.A.W. Rook & G. Bjune: Persistence of DNA from Mycobacterium tuberculosis in superficially normal lung tissue during latent infection. Lancet 356, 2133-2137 (2000)
7. Rich A.R., & R.H. Follis Jr: The effect of low oxygen tension upon the development of experimental tuberculosis. Bull Johns Hopkins Hospital 71, 345-357 (1942)
8. Zhang Y., Y Yang, A Woods, R.J. Cotter & Z. Sun: Resuscitation of dormant Mycobacterium tuberculosis by phospholipids or specific peptides. Biochem Biophys Res Commun 284, 542-547 (2001)
9. Sirgel F.A., P.R. Donald, J. Odhiambo, W. Githui, K.C. Umapathy, C.N. Paramasivan, C.M. Tam, K.M. Lam, C.W. Lam, K.M. Sole, D.A. Mitchison & the EBA Collaborative Study Group: A multicentre study of the early bactericidal activity of anti-tuberculosis drugs. J Antimicrob Chemother 45, 859-870 (2000)
10. Jindani A, CJ. Doré & D.A. Mitchison: The bactericidal and sterilising activities of antituberculosis drugs during the first 14 days. Am J Respir Crit Care Med 167, 1348-1354 (2003)
11. Bigger J.W: Treatment of staphylococcal infections with penicillin. Lancet ii, 497-500 (1944)
12. Hobby G.L. & T.F Lenert: The in vitro action of antituberculous agents against multiplying and non-multiplying microbial cells. Am Rev Tuberc Pulm Dis 76, 1031-1048 (1957)
13. Dickinson J.M. & D.A. Mitchison: Experimental models to explain the high sterilizing activity of rifampin in the chemotherapy of tuberculosis. Amer Rev Resp Dis 123, 367-371 (1981)
14. Wayne L.G & L.G. Hayes: An in vitro model for sequential study of shiftdown of Mycobacterium tuberculosis through two stages of nonreplicating persistence. Infect Immun 64, 2062-2069 (1996)
15. Hu Y, J. A. Mangan, J. Dhillon, K.M. Sole, D.A. Mitchison, P.D. Butcher & A.R.M. Coates: Detection of mRNA transcripts and active transcription in persistent Mycobacterium tuberculosis induced by exposure to rifampin or pyrazinamide. J Bacteriol 182, 6358-6365 (2000)
16. Hu Y. & A.R.M. Coates: Increased levels of sigJ mRNA in late stationary phase cultures of Mycobacterium tuberculosis detected by DNA array hybridisation. FEMS Microbiol Lett 202, 59-65 (2001)
17. Hu Y, A.R.M. Coates & D.A. Mitchison: Sterilizing activities of fluoroquinolones against rifampin-tolerant populations of Mycobacterium tuberculosis. Antimicrob Agents Chemother 47, 653-657 (2003)
18. Dhillon J. B.W. Allen, Y-M Hu, A.R.M. Coates & D.A. Mitchison: Metronidazole has no antibacterial effect in Cornell model murine tuberculosis. Int J Tuberc Lung Dis 2, 736-742 (1998)
19. McCune R, R. Tompsett & W. McDermott: The fate of Mycobacterium tuberculosis in mouse tissues as determined by the microbial enumeration technique. II. The conversion of tuberculous infection to the latent state by the administration of pyrazinamide and a companion drug. J Exp Med 104, 763-803 (1956)
20. Fox W, G.A. Ellard & D A. Mitchison: Studies on the treatment of tuberculosis undertaken by the British Medical Research Council Tuberculosis Units, 1946-1984, with relevant subsequent publications. Int J Tuberc Lung Dis 3, S231-S279 (1999)
21. Zhang Y & A. Telenti: Genetics of Drug Resistance in Mycobacterium tuberculosis. In: Molecular Genetics of Mycobacteria. Eds: Hatfull G F, Jacobs W R, ASM Press, Washington DC, 235-254 (2000)
22. Schaefer W.B: The effect of isoniazid on growing and resting tubercle bacilli. Amer Rev Tuberc 69, 125-127 (1954)
23. Zhang Y & D.A. Mitchison: The curious characteristics of pyrazinamide: a review. Int J Tuberc Lung Dis 7, 6-21 (2003)
24. Mitchison D.A. & J.B. Selkon: The bactericidal activities of antituberculous drugs. Amer Rev Tuberc 74, 109-116 (1956)
25. Tucker W.B: Comparative efficacy of three streptomycin and para-aminosalicylic acid regimens of prolonged duration in patients with previously untreated pulmonary tuberculosis. Am Rev Tuberc 72, 733-755 (1955)
26. Briggs I.L., W.R. Rochester & D.H. Shennan: Streptomycin plus thiacetazone (Thioacetazone) compared with streptomycin plus PAS and with isoniazid plus thiacetazone in the treatment of pulmonary tuberculosis in Rhodesia. Tubercle 49, 48-69 (1968)
27. Russell W.F. Jr., S.H. Dressler, G. Middlebrook & J. Denst: Implications of the phenomenon of open cavity healing for the chemotherapy of pulmonary tuberculosis. Am Rev Tuberc PuIm Dis 71, 441-446 (1955)
28. Mitchison D.A: Role of individual drugs in the chemotherapy of tuberculosis. Int J Tuberc Lung Dis 4, 796-806. (2000)
29. Grumbach F. & N. Rist: Activité antituberculeuse expérimentale de la rifampicine, dérivé de la rifamycine SV. Rev Tuberc Pneumol 31, 749-762 (1967)
30. Grosset J: The sterilizing value of rifampicin and pyrazinamide in experimental short course chemotherapy. Tubercle 59, 287-297 (1978)
31. East African/British Medical Research Council: Controlled clinical trial of short-course (6-month) regimens of chemotherapy for treatment of pulmonary tuberculosis. Lancet May 20, 1079-1085 (1972)
32. Hong Kong Chest Service/British Medical Research Council: Controlled trial of 6-month and 9-month regimens of daily and intermittent streptomycin plus isoniazid plus pyrazinamide for pulmonary tuberculosis in Hong Kong. The results up to 30 months. Am Rev Respir Dis 115, 727-735 (1977)
33. British Thoracic Association: Short course chemotherapy in pulmonary tuberculosis. Lancet 1, 1182 (1980)
34. Singapore Tuberculosis Service/British Medical Research Council: Long-term follow up of a clinical trial of six-month and four-month regimens of chemotherapy in the treatment of pulmonary tuberculosis. Am Rev Respir Dis 133, 779-783 (1986)
35. Singapore Tuberculosis Service/British Medical Research Council: Clinical trial of three 6-month regimens of chemotherapy given intermittently in the continuation phase in the treatment of pulmonary tuberculosis. Am Rev Respir Dis 132, 374-378 (1985)
36. Singapore Tuberculosis Service/British Medical Research Council: Assessment of a daily combined preparation of isoniazid, rifampin and pyrazinamide in a controlled trial of three 6-month regimens for smear-positive pulmonary tuberculosis. Am Rev Respir Dis 143, 707-712 (1991)
37. British Thoracic Association: A controlled trial of six months chemotherapy in pulmonary tuberculosis. Second Report: Results during the 24 months after the end of chemotherapy. Am Rev Respir Dis 126, 460-462 (1982)
38. th study. Am Rev Respir Dis 123, 165-170 (1981)
39. Hong Kong Chest Service/British Medical Research Council: Controlled trial of 2, 4 and 6 months of pyrazinamide in 6-month, 3 x weekly regimens for smear-positive pulmonary tuberculosis, including an assessment of a combined preparation of isoniazid, rifampinand pyrazinamide. Am Rev Respir Dis 143, 700-706 (1991)
40. East and Central African/British Medical Research Council (fifth Collaborative Study): Controlled clinical trial of 4 short-course regimens of chemotherapy (three 6-month and one 8-month) for pulmonary tuberculosis. Final report. Tubercle 67, 5-15 (1986)
41. Donald P.R., F.A.Sirgel, F.J.Botha, H.I.Seifart, D.P.Parkin, M.L.Vandenplas, B.W.Van de Wal, J.S.Maritz & D.A.Mitchison: The early bactericidal activity of isoniazid related to its dose size in pulmonary tuberculosis. Am J Respir Crit Care Med, 156, 895-900 (1997)
42. Botha F.J.H., F.A. Sirgel, D.P. Parkin, B.W. van de Wal, P.R. Donald & D.A. Mitchison: Early bactericidal activity of ethambutol, pyrazinamide and the fixed combination of isoniazid, rifampicin and pyrazinamide (Rifater) in patients with pulmonary tuberculosis. S Afr Med J, 86, 155-158 (1996)
43. Mitchison D.A: The action of antituberculosis drugs in short-course chemotherapy. Tubercle 66, 219-225 (1985)
44. Salfinger M., A. J. Crowle & L.B. Reller: Pyrazinamide and pyrazinoic acid activity against tubercle bacilli in cultured human macrophages and in the BACTEC system. J Infect Dis 162, 201-207 (1990)
45. Rastogi N., M.C. Potar & H.L. David: Pyrazinamide is not effective against intracellularly growing Mycobacterium tuberculosis. Antimicrob Agents Chemother 32, 287 (1988)
46. Heifets L., M. Higgins & B. Simon: Pyrazinamide is not active against Mycobacterium tuberculosis residing in cultured human monocyte-derived macrophages. Int J Tuberc Lung Dis 4, 491-495 (2000)
47. Global Alliance for TB Drug Development: Tuberculosis - Scientific Blueprint for tuberculosis drug development. Tuberculosis, 81, Sup 1, 1-52 (2001)
48. Wayne L.G. & K-Y. Lin: Glyoxylate metabolism and adaptation of Mycobacterium tuberculosis to survival under anaerobic conditions. Infect Immun 37, 1042-1049 (1982)
49. Batten J.C. & R.M. McCune Jr: The influence of corticotrophin and cortisone with antituberculous drugs on populations of Mycobacterium tuberculosis in tissues of mice. Brit J Exp Path 38, 424-437 (1957)
50. Tuberculosis Research Centre, Madras: Study of chemotherapy regimens of 5 and 7 months' duration and the role of corticosteroids in the treatment of sputum-positive patients with pulmonary tuberculosis in South India. Tubercle 64, 73-91 (1983)
51. Donald P.R., F.A. Sirgel, A. Venter, E. Smit, D.P. Parkin, B.W. Van de Wal, C.J. Doré & D.A. Mitchison: The early bactericidal activity of streptomycin. Int J Tuberc Lung Dis 6, 693-698 (2002)
52. Lecoeur H.F., C. Truffot-Pernot & J.H. Grosset: Experimental short-course preventive therapy of tuberculosis with rifampin and pyrazinamide. Am Rev Respir Dis 140, 1189-1193 (1989)
53. Dhillon J., R. Fielding, J. Adler-Moore, R.L. Goodall & D.A. Mitchison: The activity of low-clearance liposomal amikacin in experimental murine tuberculosis. J Antimicrob Chemother 48, 869-876 (2001)
54. Lalande V, C. Truffot-Pernot, A. Paccaly-Moulin, J. Grosset & J. Baohong: Powerful bactericidal activity of sparfloxacin (AT-4140) against Mycobacterium tuberculosis in mice. Antimicrob Agents Chemother 37, 407-413 (1993)
55. Kondo E. & K. Kanai: An experimental model of chemotherapy on dormant tuberculous infection, with particular reference to rifampicin. Japan J Med Sci Biol 41, 37-47 (1988)
56. Tuberculosis Drug Screening Program: Guest Commentary. Search for new drugs for treatment of tuberculosis. Antimicrob Agents Chemother 45, 1943-1946 (2001)
57. Lenaerts A. J. M., V. Gruppo, J. V. Brooks & I. M. Orme: Rapid in vivo screening of experimental drugs for tuberculosis using gamma interferon gene-disrupted mice. Antimicrob Agents Chemother 47, 783-785 (2003)
58. Turner D.J., S. L. Hoyle, V. A. Snewin, M-P Gares, I. N. Brown & D. B. Young: An ex vivo culture model for screening drug activity against in vivo phenotypes of Mycobacterium tuberculosis. Microbiology 148, 2929-2936 (2002)
59. Wallis R.S., S. Patil, S-H Cheon, K. Edmonds, M. Phillips, M.D. Parkins, M. Joloba, A. Namale, J.L. Johnson, L. Teixeira, R. Dietze, S. Siddiqi, R.D. Mugerwa, K. Eisenach & J.J. Ellner: Drug tolerance in Mycobacterium tuberculosis. Antmicrob Agents Chemother43, 2600-2606 (1999)